secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2025-12-09T23:59:59+00:00
Accession:  0001549595-25-000121
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix releases Phase 1 CLL/SLL data: 83% ORR, 22.1mo PFS; WM ORR 75.0% at ASH 2025
--------------------------------------------------------------------------------

- Phase 1a CLL/SLL ORR 83.0% (47 evaluable), including 4.3% complete responses; median PFS 22.1 months, DOR 20.1 months.
- Phase 1b randomized comparison: 600mg RP2D showed 83.3% ORR vs 73.7% for 200mg; PFS trend favoring 600mg.
- WM (n=28 evaluable) ORR 75.0% including 10.7% VGPR; median follow-up 8.1 months, median DOR and PFS not reached.
- Safety: well tolerated across doses; no dose-limiting toxicities, systemic fungal infections, or Grade 4 infections.
- Pivotal Phase 2 DAYBreak-CLL-201 enrolling globally; 600mg RP2D selected for further development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000121/0001549595-25-000121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000121/nrix-20251206.htm
  HTML page:      https://secwatch.observer/filing/0001549595-25-000121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer